Serina Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 29, 2024, by Serina Therapeutics, Inc. (formerly AgeX Therapeutics, Inc.). The Company is an emerging growth company incorporated in Delaware. On March 26, 2024, the Company completed a merger transaction where AgeX Therapeutics, Inc. acquired Serina Therapeutics, Inc., and subsequently changed its name to Serina Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. The document focuses on corporate governance changes rather than financial performance data.
Material Changes
- Change in Certifying Accountant: On April 29, 2024, the Audit Committee engaged Frazier & Deeter, LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Dismissal of Prior Auditor: WithumSmith+Brown, PC was dismissed and replaced by Frazier & Deeter. Withum served as the auditor prior to the March 2024 merger.
- Audit History: Withum's reports for fiscal years 2023 and 2022 did not contain adverse opinions or disclaimers, except for a qualification regarding substantial doubt about the Company's ability to continue as a going concern.
- No Disagreements: There were no disagreements between the Company and Withum regarding accounting principles, practices, or audit scope during the relevant periods.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the historical note of "substantial doubt about the Company's ability to continue as a going concern" noted in prior audit reports. The primary event reported is the administrative change of the external auditor.
Investor Verification Checklist
- Verify the transition timeline and scope of work between the outgoing auditor (WithumSmith+Brown, PC) and the incoming auditor (Frazier & Deeter, LLC).
- Review the "Letter from WithumSmith+Brown, PC" filed as Exhibit 16.1 to confirm their agreement with the Company's disclosures regarding the dismissal.
- Assess the current status of the "substantial doubt" regarding the Company's ability to continue as a going concern, as noted in prior years' audits.
- Confirm the Company's post-merger capital structure and liquidity position in subsequent filings (e.g., 10-Q or 10-K), as this 8-K does not provide updated financial statements.